A Forward Look, the Year Ahead - Featured Research on VIVUS, Inc. and Eli Lilly & Co.
(firmenpresse) - HONG KONG -- (Marketwire) -- 01/17/12 -- Today, introduced featured coverage of VIVUS, Inc. (NASDAQ: VVUS) and Eli Lilly & Co. (NYSE: LLY). Full research reports are available to readers at: .
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experienced in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected VIVUS, Inc. for its current position within the healthcare industry. VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of therapeutic drugs for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men's sexual health. A copy of this report featuring VIVUS, Inc. (NASDAQ: VVUS) is available at: .
Bollinger Report is featuring Eli Lilly & Co. for its changing role within the healthcare industry. Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries. Its products are sold in approximately 125 countries. To download researches and analysis on Eli Lilly & Co. (NYSE: LLY) we welcome investors to visit: .
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.
Contact:
Martin Schwartz
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.01.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 104765
Anzahl Zeichen: 0
contact information:
Town:
HONG KONG
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"A Forward Look, the Year Ahead - Featured Research on VIVUS, Inc. and Eli Lilly & Co."
steht unter der journalistisch-redaktionellen Verantwortung von
Bollinger Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
